Amended Statement of Ownership (sc 13g/a) (2022)

Amended Statement of Ownership (sc 13g/a) (1)

Amended Statement of Ownership (sc 13g/a)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Akouos, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00973J101

(CUSIP Number)

August 25, 2022

(Date of Event Which Requires Filing of thisStatement)

Check the appropriate box to designate the rule pursuant to whichthis Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*

The remainder of this cover page shall be filled outfor a reporting person’s initial filing on this form with respectto the subject class of securities, and for any subsequentamendment containing information which would alter the disclosuresprovided in a prior cover page.

The information required in the remainder of this cover page shallnot be deemed to be “filed” for the purpose of Section 18 of theSecurities Exchange Act of 1934 (“Act”) or otherwise subject to theliabilities of that section of the Act but shall be subject to allother provisions of the Act (however, see the Notes).

1

NAMES OF REPORTING PERSONS

Pivotal bioVenture Partners Fund I, L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

1

NAMES OF REPORTING PERSONS

Pivotal bioVenture Partners Fund I G.P., L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

(Video) Schedule 13G Instructions

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

1

NAMES OF REPORTING PERSONS

Pivotal bioVenture Partners Fund I U.G.P., Ltd.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

Pivotal Partners Ltd

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

Pivotal Life Sciences Holdings Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

(Video) Schedule 13D Instructions

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

Nan Fung Group Holdings Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

NF Investment Holdings Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

Nan Fung Life Sciences Holdings Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

(Video) Types of Institutional SEC Filings (13F, 13G & 13D)

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

NFLS Beta Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

1

NAMES OF REPORTING PERSONS

NFLS Platform Holdings Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEEINSTRUCTIONS)

(a)☐(b)☒

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBEROF

SHARES

BENEFICIALLY

OWNEDBY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

6

SHARED VOTING POWER

1,794,088

7

SOLE DISPOSITIVE POWER

8

SHARED DISPOSITIVE POWER

1,794,088

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTINGPERSON

1,794,088

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDESCERTAIN SHARES (SEE INSTRUCTIONS)

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.9%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

Item1(a).

Name of Issuer:

Akouos, Inc. (the “Issuer”)

Item1(b).

Address of Issuer’s Principal ExecutiveOffices:

645 Summer Street, Suite 200

Boston, MA 02210

Item2(a).

Names of Persons Filing:

The name of the persons filing this report (the “ReportingPersons”) are:

(i)

Pivotal bioVenture Partners Fund I, L.P.(“Pivotal”)

(Video) Wall Street Words word of the day = Form 13-G

(ii)

Pivotal bioVenture Partners Fund I G.P., L.P.(“Pivotal GP”)

(iii)

Pivotal bioVenture Partners Fund I U.G.P., Ltd. (the“Ultimate General Partner”)

(iv)

Pivotal Partners Ltd (“Pivotal Partners”)

(v)

Pivotal Life Sciences Holdings Limited (“Pivotal LifeSciences”)

(vi)

Nan Fung Group Holdings Limited (“NFGHL”)

(vii)

NF Investment Holdings Limited (“NFIHL”)

(viii)

Nan Fung Life Sciences Holdings Limited (“Nan FungLife Sciences”)

(ix)

NFLS Beta Limited

(x)

NFLS Platform Holdings Limited

Item2(b).

Address of Principal Business Office or, ifNone, Residence:

The address of the principal business office of Pivotal, Pivotal GPand the Ultimate General Partner is:

501, Second Street, Suite 200

San Francisco, CA 94107

The registered office address of Pivotal Partners and Pivotal LifeSciences is:

Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman,KY1-1111, CaymanIslands

The address of the principal business office of NFGHL is:

23rd Floor,Nan Fung Tower,

88 Connaught Road C& 173 Des Voeux Road C, Central, HongKong.

The registered office address of NFIHL is:

Vistra Corporate Services Centre, Wickhams Cay II,

Road Town, Tortola, VG1110, British Virgin Islands.

Item2(c).

Citizenship:

PivotalCayman Islands
Pivotal GPCayman Islands
The Ultimate General PartnerCayman Islands
Pivotal PartnersCayman Islands
Pivotal Life SciencesCayman Islands
NFGHLBritish Virgin Islands
NFIHLBritish Virgin Islands
Nan Fung Life SciencesBritish Virgin Islands
NFLSBritish Virgin Islands
NFLS PlatformCayman Islands
Item2(d).

Title of ClassofSecurities:

Common Stock, par value $0.0001 (“Common Stock”)

Item2(e).

CUSIP Number:

00973J101

Item3.

If this statement is filed pursuant to§§240.13d-1(b) or 240.13d-2(b) or (c), check whether theperson filing is a:

Not applicable.

Item4.

Ownership.

The information required by this item with respect to eachReporting Person is set forth in Rows 5 through 9 and 11 of thecover page to this Schedule 13G. The ownership percentages arebased on 36,899,235 outstanding shares of Common Stock as reportedin the Issuer’s Form 10-Qfiled August15, 2022.

Pivotal directly holds 1,794,088 shares of Common Stock. Pivotal GPis the general partner of Pivotal. The Ultimate General Partner isthe general partner of Pivotal GP. The Ultimate General Partner iswholly-owned by Pivotal Partners. Pivotal Partners is wholly-ownedby Pivotal Life Sciences. Pivotal Life Sciences is wholly-owned byNan Fung Life Sciences, and Nan Fung Life Sciences is wholly ownedby NFIHL, which is wholly owned by NFGHL. The members of theExecutive Committee of NFGHL make investment decisions with respectto the securities of the Issuer held by Pivotal. Mr.Kam ChungLeung, Mr.Frank Kai Shui Seto, Mr.Vincent Sai SingCheung, Mr.Pui Kuen Cheung, Mr.Kin Ho Kwok,Ms.Vanessa Tih Lin Cheung, Mr.Meng Gao andMr.Chun Wai Nelson Tang are the members of the ExecutiveCommittee of NFGHL.

Item5.

Ownership of Five Percent or Less of aClass.

If this statement is being filed to report the fact that as of thedate hereof the Reporting Person has ceased to be the beneficialowner of more than five percent of the class of securities, checkthe following☒.

Item6.

Ownership of More than Five Percent on Behalf ofAnother Person.

Not applicable.

Item7.

Identification and Classification of theSubsidiary Which Acquired the Security Being Reported on by theParent Holding Company or Control Person.

Not applicable.

Item8.

Identification and Classification of Members ofthe Group.

Not applicable.

Item9.

Notice of Dissolution of Group.

Not applicable.

Item10.

Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of its knowledge andbelief, each of the undersigned certifies that the information setforth in this statement is true, complete and correct.

Date: August 25, 2022

PIVOTAL BIOVENTURE PARTNERS FUND I,L.P.
By: PIVOTAL BIOVENTURE PARTNERSFUND I G.P., L.P.
Its General Partner,
By: PIVOTAL BIOVENTURE PARTNERSFUND I U.G.P., LTD.
Its General Partner,
By:

/s/ Robert Hopfner

Robert Hopfner
Authorized Signatory
PIVOTAL BIOVENTURE PARTNERS FUND IG.P., L.P.
By: PIVOTAL BIOVENTURE PARTNERSFUND I U.G.P., LTD
Its General Partner,
By:

/s/ Robert Hopfner

Robert Hopfner
Authorized Signatory
PIVOTAL BIOVENTURE PARTNERS FUND IU.G.P., LTD.
By:

/s/ Robert Hopfner

Robert Hopfner
Authorized Signatory
PIVOTAL PARTNERS LTD
By:

/s/ Sun Xintong

Name:Sun Xintong
Title:Director
PIVOTAL LIFE SCIENCES HOLDINGSLIMITED
By:

/s/ Sun Xintong

Name:Sun Xintong
Title:Director
NAN FUNG GROUP HOLDINGSLIMITED
By:

/s/ Tang Chun Wai Nelson

Tang Chun Wai Nelson
Director
NF INVESTMENT HOLDINGSLIMITED
By:

/s/ Tang Chun Wai Nelson

Tang Chun Wai Nelson

Director

NAN FUNG LIFE SCIENCES HOLDINGSLIMITED
By:

/s/ Sun Xintong

Sun Xintong

Director

NFLS BETA LIMITED
By:

/s/ Sun Xintong

Sun Xintong

Director

NFLS PLATFORM HOLDINGSLIMITED
By:

/s/ Sun Xintong

Sun Xintong

Director

Akouos (NASDAQ:AKUS)
Historical Stock Chart
From Aug 2022 to Sep 2022

Akouos (NASDAQ:AKUS)
Historical Stock Chart
From Sep 2021 to Sep 2022

Amended Statement of Ownership (sc 13g/a) (4){{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}}
  • Share on Facebook Share on Twitter Share on Email

Loading Messages....

See More Message Board Posts

Loading Messages....

`, data() { return {tabs: [] }; }, created() { this.tabs = this.$children; }, methods: { selectTab(selectedTab) { this.tabs.forEach(tab => { tab.isActive = (tab.name == selectedTab.name); }); } }});Vue.component('tab', { template: `

`, props: { name: { required: true }, selected: { default: false} }, data() { return { isActive: false }; }, computed: { href() { return '#' + this.name.toLowerCase().replace(/ /g, '-'); } }, mounted() { this.isActive = this.selected; }});Vue.component('newslist', { template: `

No News, be the first to add your company releases.

`, props: { source: { required: true }, rawarticles: { required: true }, limit: { default: 12 } }, methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){ return _.uniqBy(articles, "headline");} }, data() { return { loaded: false, articles: [] }; }, mounted() { this.processData(this.rawarticles); }});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Amended Statement of Ownership (sc 13g\/a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88920313\/amended-statement-of-ownership-sc-13g-a","source":"Edgar (US Regulatory)","date":"Thu Aug 25, 2022 ","time":"4:08 PM (1 week ago)"},{"headline":"Amended Statement of Ownership (sc 13g\/a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88840438\/amended-statement-of-ownership-sc-13g-a","source":"Edgar (US Regulatory)","date":"Mon Aug 15, 2022 ","time":"5:04 PM (3 weeks ago)"},{"headline":"Quarterly Report (10-q)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88836164\/quarterly-report-10-q","source":"Edgar (US Regulatory)","date":"Mon Aug 15, 2022 ","time":"7:25 AM (3 weeks ago)"},{"headline":"Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88835840\/akouos-reports-second-quarter-2022-financial-resul","source":"GlobeNewswire Inc.","date":"Mon Aug 15, 2022 ","time":"7:00 AM (3 weeks ago)"},{"headline":"Statement of Ownership (sc 13g)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88556673\/statement-of-ownership-sc-13g","source":"Edgar (US Regulatory)","date":"Fri Jul 08, 2022 ","time":"5:01 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460483\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:05 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460480\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:05 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460475\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:04 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460470\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:03 PM (2 months ago)"},{"headline":"Current Report Filing (8-k)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460425\/current-report-filing-8-k","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:02 PM (2 months ago)"},{"headline":"Statement of Ownership (sc 13g)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88186619\/statement-of-ownership-sc-13g","source":"Edgar (US Regulatory)","date":"Mon May 23, 2022 ","time":"4:31 PM (3 months ago)"},{"headline":"Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88159793\/akouos-presents-nonclinical-data-supporting-the-pl","source":"GlobeNewswire Inc.","date":"Thu May 19, 2022 ","time":"7:00 AM (4 months ago)"}],"All News": [{"headline":"Amended Statement of Ownership (sc 13g\/a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88920313\/amended-statement-of-ownership-sc-13g-a","source":"Edgar (US Regulatory)","date":"Thu Aug 25, 2022 ","time":"4:08 PM (1 week ago)"},{"headline":"Amended Statement of Ownership (sc 13g\/a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88840438\/amended-statement-of-ownership-sc-13g-a","source":"Edgar (US Regulatory)","date":"Mon Aug 15, 2022 ","time":"5:04 PM (3 weeks ago)"},{"headline":"Quarterly Report (10-q)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88836164\/quarterly-report-10-q","source":"Edgar (US Regulatory)","date":"Mon Aug 15, 2022 ","time":"7:25 AM (3 weeks ago)"},{"headline":"Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88835840\/akouos-reports-second-quarter-2022-financial-resul","source":"GlobeNewswire Inc.","date":"Mon Aug 15, 2022 ","time":"7:00 AM (3 weeks ago)"},{"headline":"Statement of Ownership (sc 13g)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88556673\/statement-of-ownership-sc-13g","source":"Edgar (US Regulatory)","date":"Fri Jul 08, 2022 ","time":"5:01 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460483\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:05 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460480\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:05 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460475\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:04 PM (2 months ago)"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460470\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:03 PM (2 months ago)"},{"headline":"Current Report Filing (8-k)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88460425\/current-report-filing-8-k","source":"Edgar (US Regulatory)","date":"Mon Jun 27, 2022 ","time":"5:02 PM (2 months ago)"},{"headline":"Statement of Ownership (sc 13g)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88186619\/statement-of-ownership-sc-13g","source":"Edgar (US Regulatory)","date":"Mon May 23, 2022 ","time":"4:31 PM (3 months ago)"},{"headline":"Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/akouos-AKUS\/stock-news\/88159793\/akouos-presents-nonclinical-data-supporting-the-pl","source":"GlobeNewswire Inc.","date":"Thu May 19, 2022 ","time":"7:00 AM (4 months ago)"}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});

More Akouos, Inc. News Articles

FAQs

What does 13G A ownership mean? ›

What Is Schedule 13G? The Securities and Exchange Commission (SEC) Schedule 13G form is an alternative filing for the Schedule 13D form and is used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.

What is a 13G amendment? ›

After crossing the 10% threshold, Qualified Institutional Investors must file an amendment to their Schedule 13G within 10 calendar days following the close of the month to report any ownership change of 5% or more as of the close of the month.

What is Form SC 13G A used for? ›

Schedule 13G is an SEC form that is similar to Schedule 13D.

It is used to report a party's ownership of stock that is over 5% of a class of equity in a company.

Who needs to file 13G? ›

(g) Any person who has reported an acquisition of securities in a statement on Schedule 13G (§ 240.13d-102) pursuant to paragraph (b) of this section, or has become obligated to report on the Schedule 13G (§ 240.13d-102) but has not yet filed the Schedule, and thereafter ceases to be a person specified in paragraph (b ...

When can you file a 13G amendment? ›

Any person who has filed a Schedule 13G must file an annual amendment to the Schedule within 45 days after the end of the calendar year, to report any changes in the information presented. (No Amendment is required if there have been no changes). This obligation is not limited to institutional investors.

What is Statement of changes in beneficial ownership? ›

SEC Form 5: Annual Statement of Changes in Beneficial Ownership of Securities is a document that company insiders must file with the Securities and Exchange Commission if they have conducted transactions during the year that they did not previously report via a Form 4.

Videos

1. Schedule 13D
(Anthony L.G., PLLC)
2. How to Prepare "Beneficial Ownership Tables" for 5% Stockholders for the Proxy
(Zippy Point)
3. Does Schedule 13-D Matter To Me As A Day Trader?
(Socrates Trading)
4. How to Read Form 4 Stocks, SEC. Track Insider Trading.
(StonkSlayd)
5. BIG FILING! 13G REPORTING MODERNIZATION
(Charlie's Vids)
6. Sections 13 and 16 Reporting Requirements
(Anthony L.G., PLLC)

Top Articles

You might also like

Latest Posts

Article information

Author: Greg Kuvalis

Last Updated: 11/02/2022

Views: 5615

Rating: 4.4 / 5 (75 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Greg Kuvalis

Birthday: 1996-12-20

Address: 53157 Trantow Inlet, Townemouth, FL 92564-0267

Phone: +68218650356656

Job: IT Representative

Hobby: Knitting, Amateur radio, Skiing, Running, Mountain biking, Slacklining, Electronics

Introduction: My name is Greg Kuvalis, I am a witty, spotless, beautiful, charming, delightful, thankful, beautiful person who loves writing and wants to share my knowledge and understanding with you.